Blood Pressure
Volume 31, 2022 - Issue 1
Research Article
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified
Murray Eslera Baker Heart and Diabetes Institute, Human Neurotransmitters Laboratory and Monash University, Melbourne, AustraliaCorrespondence[email protected]
https://orcid.org/0000-0002-8755-7658View further author information
https://orcid.org/0000-0002-8755-7658View further author information, Sverre E. Kjeldsenb Department of Cardiology, Ullevaal Hospital, University of Oslo, Oslo, Norwayhttps://orcid.org/0000-0003-2389-0272View further author information
https://orcid.org/0000-0003-2389-0272View further author information, Atul Pathakc Department of Cardiology, and UMR UT3 CNRS 5288 Hypertension and heart failure: molecular and clinical investigations, INI-CRCT F-CRIN, GREAT Networks, Centre Hospitalier Princesse Grace, Monte Carlo, Monaco;https://orcid.org/0000-0001-6151-0096View further author information
https://orcid.org/0000-0001-6151-0096View further author information, Guido Grassid University of Milano-Bicocca, Milan, Italyhttps://orcid.org/0000-0003-1922-6547View further author information
https://orcid.org/0000-0003-1922-6547View further author information, Reinhold Kreutze Charité – Medical University of Berlin, Institute of Clinical Pharmacology and Toxicology, Berlin, Germanyhttps://orcid.org/0000-0002-4818-211XView further author information
https://orcid.org/0000-0002-4818-211XView further author information & Giuseppe Manciad University of Milano-Bicocca, Milan, Italyhttps://orcid.org/0000-0003-0942-3176View further author information
https://orcid.org/0000-0003-0942-3176View further author information